Bausch + Lomb Earnings Call Transcripts
Fiscal Year 2026
-
BL1332 missed the phase II primary endpoint, but both doses favored vehicle across all SPID estimates, with nominal significance for the high dose at six hours. Exploratory results showed more pain-free patients and earlier epithelial recovery; discussions on larger confirmatory studies are planned.
-
Q3 revenue rose 8% on a constant-currency basis, while adjusted EBITDA increased 34% and free cash flow reached $178M. FY 2026 revenue and adjusted EBITDA guidance were raised, with net leverage down to 4.1x.
-
A novel dual-action dry eye therapy demonstrated rapid, significant efficacy at day 15 with reduced dosing and strong tolerability, guiding a focused phase III strategy. BL1332, a potent TRPV1 antagonist, showed dramatic pain relief in a phase I-B study, supporting broader development in ocular pain. Both assets are expected to drive substantial long-term growth.
-
Q2 2026 saw 8% revenue growth and 28% adjusted EBITDA growth, with strong performance across all segments and significant margin expansion. Guidance for full-year revenue and EBITDA was raised, supported by robust cash flow and continued deleveraging.
-
Management outlined a strategy focused on operational reliability, innovation, and financial excellence, targeting 5%-7% annual growth and significant margin expansion by 2028. Key innovations like Project Halo and ELIOS are set to drive future growth, with a robust pipeline and disciplined capital allocation supporting long-term market leadership.
-
Two major contact lens innovations are advancing: Project Halo, a bioactive daily lens with HA for superior comfort, targets a 2028 U.S. launch, while a differentiated myopia control lens for children is set for 2029. Both leverage efficient manufacturing and aim to expand market share.
-
The meeting confirmed a quorum and addressed four proposals, including director elections, executive compensation, and auditor appointment, with all voted proposals approved. No shareholder questions were received, and final results will be disclosed in a Form 8-K.
-
Q1 2026 delivered 6% revenue growth and 59% adjusted EBITDA growth, with margin expansion and strong performance across all segments. Guidance for 2026 was raised, reflecting confidence in continued growth, margin improvement, and robust pipeline execution.
-
BL 1107, a novel neuroprotective glaucoma therapy, shows significant vision gains and is on track for phase II readout in H2, with phase III to follow. ELIOS, an implant-free excimer laser MIGS, showed durable IOP reduction and medication-free rates, targeting U.S. approval in late 2026. Both assets are expected to drive substantial growth and address major unmet needs.
-
The conference highlighted a robust innovation-driven strategy, with major product launches in consumer, contact lens, pharma, and surgical segments expected through 2029. Margin expansion, double-digit EPS growth, and strong free cash flow are forecast, supported by operational excellence and disciplined capital allocation.
Fiscal Year 2025
-
Record Q4 and full year results featured 7% revenue and 27% adjusted EBITDA growth, with all segments contributing and strong operating leverage. 2026 guidance calls for 5โ7% revenue growth and 15% adjusted EBITDA growth, supported by robust product launches, margin expansion, and continued execution.
-
Management outlined a multi-year transformation focused on operational, financial, and innovation excellence, with Vision 27 driving margin and sales growth. Key product launches and a robust pipeline support a 5%-7% revenue CAGR and 600 basis point margin improvement by 2028.
-
Management outlined a strategy for 5%-7% annual revenue growth and a 23% EBITDA margin by 2028, driven by premium product launches, operational efficiencies, and a robust R&D pipeline. Key innovations include a bioactive contact lens, dual-action dry eye therapy, and precision medicine in retina, with regular launches planned through 2032.
-
Q3 2025 saw 6% revenue growth year-over-year, with strong performance across all segments and standout results in pharmaceuticals, particularly MIEBO. Margin expansion, disciplined cost management, and robust cash flow support a positive outlook, with guidance reaffirmed and a focus on innovation and financial excellence.
-
Strong top-line growth, operational improvements, and a robust innovation pipeline are driving performance, with a focus on margin expansion and comprehensive eye care. Key product launches and AI-driven marketing are fueling growth, while Investor Day in November will outline long-term targets.
-
Q2 revenue grew 3% year-over-year, with strong gains in dry eye and contact lens portfolios, despite a major recall and generics headwinds. Full-year guidance was raised, reflecting confidence in recovery, margin expansion, and robust R&D pipeline.
-
Q1 saw 5% overall growth, with strong gains in surgical and lens segments and continued leadership in dry eye. The pipeline is robust, with multiple launches planned and a focus on innovation. Tariff impacts are now expected to be fully offset in 2025, and guidance remains positive for the year.
-
Q1 2025 saw 5% constant currency revenue growth, led by strong vision care and surgical segments, despite a one-time Invista recall impact. Full-year guidance was raised, with robust innovation and mitigation strategies in place for tariff risks.
-
The conference highlighted a strategic transformation with strong global growth, a robust innovation pipeline, and a focus on operational excellence. Key product launches and targeted M&A are set to drive above-market growth, with new clinical trials and launches planned through 2031.
Fiscal Year 2024
-
Double-digit revenue growth continued in Q4 and full-year 2024, driven by innovation, new product launches, and strong execution across all segments. 2025 guidance anticipates 5.5%โ7.5% constant currency growth, margin expansion, and positive free cash flow, with investments in R&D and DTC expected to support long-term growth.
-
Revenue grew 19% year-over-year, driven by strong performance in all segments, especially dry eye and contact lenses. Margin expansion continued, with robust product launches and digital investments supporting future growth. Full-year guidance was raised, reflecting ongoing momentum.
-
Delivered 20% constant currency revenue growth with strong performance across all segments and geographies. Raised full-year revenue and EBITDA guidance, driven by successful product launches and continued investment in innovation, despite currency and margin headwinds.